ArticleEFSA journal. European Food Safety Authority2026
Lack of confirmatory data following Article 12 MRL reviews for dicloran, fenazaquin and tebufenozide.
Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Setting of an import tolerance for fenazaquin in teas.EFSA journal. European Food Safety Authority · 2026Article
- Lack of confirmatory data following Article 12 MRL reviews for dicloran, fenazaquin and tebufenozide.EFSA journal. European Food Safety Authority · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In accordance with Article 31 of Regulation (EC) No 178/2002, the European Commission mandated EFSA to issue a statement concerning confirmatory data that were not submitted by the set deadline by the applicant following Article 12 MRL reviews under Regulation (EC) No 396/2005 for the active substances dicloran, fenazaquin and tebufenozide. EFSA assessed the availability and completeness of the confirmatory information and prepared a statement providing a conclusion on whether the existing tentative maximum residue levels (MRLs) are supported by data. The statement also included indications to risk managers whether the tentative MRLs currently established by Regulation (EC) No 396/2005 could be maintained. Before finalisation, the statement was circulated to Member States for consultation via a written procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.